An Imaging Survey of Early-Type Barred Galaxies

This paper presents the results of a high-resolution imaging survey, using both ground-based and Hubble Space Telescope images, of a complete sample of nearby barred S0--Sa galaxies in the field, with a particular emphasis on identifying and measuring central structures within the bars: secondary bars, inner disks, nuclear rings and spirals, and off-plane dust. A discussion of the frequency and statistical properties of the various types of inner structures has already been published. Here, we present the data for the individual galaxies and measurements of their bars and inner structures. We set out the methods we use to find and measure these structures, and how we discriminate between them. In particular, we discuss some of the deficiencies of ellipse fitting of the isophotes, which by itself cannot always distinguish between bars, rings, spirals, and dust, and which can produce erroneous measurements of bar sizes and orientations.Comment: LaTeX, 66 pages (including 42 figures, 36 in color). To appear in The Astrophysical Journal Supplement. Full-resolution and text-only versions available at http://www.iac.es/galeria/erwin/research

Face-on galaxies NGC 524 and NGC 6340: chemically decoupled nuclei and inclined circumnuclear disks

Central regions of the early-type disk galaxies NGC 524 and NGC 6340 have been investigated with the Multi-Pupil Field Spectrograph at the 6m telescope of the Special Astrophysical Observatory of the Russian Academy of Sciences. I confirm the existence of chemically distinct stellar nuclei in these galaxies which have been claimed earlier. The metallicity differences which are found between the nuclei and the bulges, 0.5 - 1.0 kpc from the centers, reach 0.5 - 0.6 dex. Both nuclei are magnesium overabundant, but the bulges have different magnesium-to-iron ratios: it is solar in NGC 6340 and the same as the nuclear one in NGC 524. The kinematical and morphological analyses reveal the existence of inclined central disks in these galaxies. In NGC 524 the central disk consists of stars, dust, and ionized gas; its extension may be as large as up to R=3 kpc, and it is inclined by more than 20 deg to the global galactic plane. In NGC 6340 only a gaseous polar disk with the radius less than 500 pc is detected.Comment: 25 pages, 15 figures, to appear in Astronomical Journal, August2000 issu

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic

During the COVID-19 outbreak, the European Reference Network on Rare Bone Diseases (ERN BOND) coordination team and Italian rare bone diseases healthcare professionals created the "COVID-19 Helpline for Rare Bone Diseases" in an attempt to provide high-quality information and expertise on rare bone diseases remotely to patients and healthcare professionals. The present position statement describes the key characteristics of the Helpline initiative, along with the main aspects and topics that recurrently emerged as central for rare bone diseases patients and professionals. The main topics highlighted are general recommendations, pulmonary complications, drug treatment, trauma, pregnancy, children and elderly people, and patient associations role. The successful experience of the "COVID-19 Helpline for Rare Bone Diseases" launched in Italy could serve as a primer of gold-standard remote care for rare bone diseases for the other European countries and globally. Furthermore, similar COVID-19 helplines could be considered and applied for other rare diseases in order to implement remote patients' care

Acute Delta Hepatitis in Italy spanning three decades (1991–2019): Evidence for the effectiveness of the hepatitis B vaccination campaign

Updated incidence data of acute Delta virus hepatitis (HDV) are lacking worldwide. Our aim was to evaluate incidence of and risk factors for acute HDV in Italy after the introduction of the compulsory vaccination against hepatitis B virus (HBV) in 1991. Data were obtained from the National Surveillance System of acute viral hepatitis (SEIEVA). Independent predictors of HDV were assessed by logistic-regression analysis. The incidence of acute HDV per 1-million population declined from 3.2 cases in 1987 to 0.04 in 2019, parallel to that of acute HBV per 100,000 from 10.0 to 0.39 cases during the same period. The median age of cases increased from 27 years in the decade 1991-1999 to 44 years in the decade 2010-2019 (p < .001). Over the same period, the male/female ratio decreased from 3.8 to 2.1, the proportion of coinfections increased from 55% to 75% (p = .003) and that of HBsAg positive acute hepatitis tested for by IgM anti-HDV linearly decreased from 50.1% to 34.1% (p < .001). People born abroad accounted for 24.6% of cases in 2004-2010 and 32.1% in 2011-2019. In the period 2010-2019, risky sexual behaviour (O.R. 4.2; 95%CI: 1.4-12.8) was the sole independent predictor of acute HDV; conversely intravenous drug use was no longer associated (O.R. 1.25; 95%CI: 0.15-10.22) with this. In conclusion, HBV vaccination was an effective measure to control acute HDV. Intravenous drug use is no longer an efficient mode of HDV spread. Testing for IgM-anti HDV is a grey area requiring alert. Acute HDV in foreigners should be monitored in the years to come

Paul Valéry, Il Cimitero Marino e altre poesie

Presentazione e commento dei testi di A. Sann

Reply to the article "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy"

We would like to comment on the review article entitled “Manage- ment of status epilepticus in adults. Position paper of the Italian League against Epilepsy” [1]. This article updates the previous article published by the same Italian League against Epilepsy in 2006. In particular, the updating regards some drugs (levetiracetam, lacosamide, midazolam, etc.) that were not available at that time, even if some of these have not yet obtained the specific indication to treat status epilepticus (SE) and their use is considered off-label

Surgery Versus ATMPs: An Example From Ophthalmology

Advanced therapy medicinal products (ATMPs) are the new frontier of medicine. Advanced therapy medicinal products are set out to satisfy unmet medical needs and provide new innovative, cutting-edge therapies for serious or life-threatening diseases, thus providing new therapeutic options for people with few or no possibility of treatment. They are divided into four groups including gene therapy medicinal products, cell-based therapy medicinal products, tissue-engineered products, and combined ATMPs, which in Europe refer to products that incorporate one or more medical devices with any of the previously mentioned ATMPs as part of the advanced medicine product (AIFA, 2017; Ten Ham et al., 2018). Advanced therapy medicinal products can potentially have long-term benefits, thus bringing a long-lasting positive impact on patient health. Advanced therapy medicinal product therapies are often administered just once or twice, which gives patients the possibility to heal quickly compared to traditional therapies. They also provide a long-term saving opportunity, both in terms of costs of treatments and procedures that are no longer necessary and in terms of quality of life and productivity. The resolution of the patient’s illness has a monetary impact on the patient, the patient’s caretakers, and especially on the society (Alliance for Regenerative Medicine, 2019). The aim of this paper was to provide an overview on the use of ATMPs approved in Europe, with a focus on blindness and visual impairment and the related economic burden. In this case study, the effective cost of a blind patient in different European countries was compared after treatment with ATMPs or traditional therapies, focusing on visual impairment caused by corneal opacity. Our evaluation includes an overview of the global economic impact of the two types of therapies on the society. We estimated direct healthcare costs, direct non-healthcare costs, and labor productivity losses, to include costs on healthcare, services, patients, their families and for the society in general. We could conclude that the costs of the two therapeutic approaches are comparable